Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

November 29, 2006 09:31 ET

Resverlogix Lead Compound RVX-208 Increases ApoA-I by 150% in First 24 Hours

Latest results provide evidence of a transcriptional mode of action. Accelerated clinical development path planned for acute cardiovascular disease treatment.

CALGARY, ALBERTA--(CCNMatthews - Nov. 29, 2006) - Resverlogix Corp. ("Resverlogix") (TSX:RVX), is pleased to announce that its clinical candidate, RVX-208, can rapidly increase plasma levels of ApoA-I up to 150% relative to control in animals in the first 24 hours. The significance of this study is that a fast and sustained increase of ApoA-I are believed to benefit patients suffering from acute cardiovascular complications, such as acute coronary syndrome (ACS) and post myocardial infarction (MI).

In previously announced studies, Resverlogix stated that RVX-208 substantially increased the plasma levels of ApoA-I up to 180% following 7 days treatment. Taken together, the data solidly demonstrates that in animal models RVX-208 rapidly increases the production of ApoA-I and that the large elevations of ApoA-I are sustained over time.

"We are pleased to observe a rapid onset of action for RVX-208, indicating that our compounds work through a transcriptional mechanism to up-regulate ApoA-I," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President of Clinical Development. "Furthermore, this observation lends support for an accelerated development path for RVX-208 including acute atherosclerotic diseases such as ACS, MI and stroke besides chronic cardiovascular conditions. We are exploring these options as we move into the clinic in Q1 of 2007," said Dr. Johansson.

According to the American Heart Association, acute cardiovascular diseases account for more than US $142 billion in direct and indirect costs in North America.

"These findings corroborate our business strategy - to develop novel compounds that help a large spectrum of patients suffering from cardiovascular diseases. Additionally we believe our pending life science partner for NexVasTM Plaque Regression technology will save considerable time to commercialization," stated Kenneth E. Lebioda Senior Vice President of Business & Market Development. Mr. Lebioda added further, "Resverlogix's platform is very well positioned to be a leader in the acute management of coronary artery disease. Evidence is mounting that RVX-208 could offer a distinct advantage in the treatment of cardiovascular disease over current technologies such as statins and other lipid regulating drugs that take months to reach full effect."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR), is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company's second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis, with a TGF- Beta inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Kenneth Lebioda
    Senior Vice President, Business & Market Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Email: ken@resverlogix.com
    or
    Resverlogix Corp.
    Theresa Kennedy
    Vice President, Corporate Communications
    (604) 538-7072
    (403) 256-8495 (FAX)
    Email: Theresa@resverlogix.com
    Website: www.resverlogix.com